Issues in the management of high-risk localized sarcomas

Current Problems in Cancer

Volumn 37, Issue 2, 2013, Pages 62-73

  Cardona, Kenneth ^a   Movva, Sujana ^b  

^a EMORY UNIVERSITY   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOXORUBICIN; EPIRUBICIN; IFOSFAMIDE; METHOTREXATE; TRABECTEDIN; VINCRISTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CHEMORADIOTHERAPY; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG MEGADOSE; EXTERNAL BEAM RADIOTHERAPY; HISTOPATHOLOGY; HUMAN; LIPOSARCOMA; LOCAL RECURRENCE FREE SURVIVAL; MELANOMA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; OVERALL SURVIVAL; PATIENT CARE; POSTOPERATIVE CARE; PROGRESSION FREE SURVIVAL; RADIATION DOSE; SARCOMA; SOFT TISSUE SARCOMA; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; HUMANS; LIMB SALVAGE; NEOPLASM RECURRENCE, LOCAL; ORGAN SPARING TREATMENTS; SARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84878488681     PISSN: 01470272     EISSN: 15356345     Source Type: Journal    
DOI: 10.1016/j.currproblcancer.2013.03.002     Document Type: Article

References (80)

1. Rosenberg S.A., Tepper J., Glatstein E., et al. The treatment of soft-tissue sarcomas of the extremities: prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy. Ann Surg 1982, 196:305-315.
2. Nurkin S.J., Kane J.M. Margin status, local recurrence, and survival: correlation or causation?. Surg Oncol Clin N Am 2012, 21:255-267.
3. Ferrone M.L., Raut C.P. Modern surgical therapy: limb salvage and the role of amputation for extremity soft-tissue sarcomas. Surg Oncol Clin N Am 2012, 21:201-213.
4. Cahlon O., Brennan M.F., Jia X., et al. A postoperative nomogram for local recurrence risk in extremity soft tissue sarcomas after limb-sparing surgery without adjuvant radiation. Ann Surg 2012, 255:343-347.
5. Pisters P.W., Harrison L.B., Leung D.H., et al. Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma. J Clin Oncol 1996, 14:859-868.
6. Yang J.C., Chang A.E., Baker A.R., et al. Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol 1998, 16:197-203.
7. Pisters P.W., Leung D.H., Woodruff J., et al. Analysis of prognostic factors in 1,041 patients with localized soft tissue sarcomas of the extremities. J Clin Oncol 1996, 14:1679-1689.
8. Baldini E.H., Goldberg J., Jenner C., et al. Long-term outcomes after function-sparing surgery without radiotherapy for soft tissue sarcoma of the extremities and trunk. J Clin Oncol 1999, 17:3252-3259.
9. Stojadinovic A., Leung D.H., Hoos A., et al. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg 2002, 235:424-434.
10. Lahat G., Tuvin D., Wei C., et al. New perspectives for staging and prognosis in soft tissue sarcoma. Ann Surg Oncol 2008, 15:2739-2748.
11. Clark M.A., Fisher C., Judson I., et al. Soft-tissue sarcomas in adults. N Engl J Med 2005, 353:701-711.
12. Bowden L., Booher R.J. The principles and technique of resection of soft parts for sarcoma. Surgery 1958, 44:963-977.
13. Midis G.P., Pollock R.E., Chen N.P., et al. Locally recurrent soft tissue sarcoma of the extremities. Surgery 1998, 123:666-671.
14. Gronchi A., Casali P.G., Mariani L., et al. Status of surgical margins and prognosis in adult soft tissue sarcomas of the extremities: a series of patients treated at a single institution. J Clin Oncol 2005, 23:96-104.
15. Trovik C.S., Bauer H.C., Alvegard T.A., et al. Surgical margins, local recurrence and metastasis in soft tissue sarcomas: 559 surgically-treated patients from the Scandinavian Sarcoma Group Register. Eur J Cancer 2000, 36:710-716.
16. Zagars G.K., Ballo M.T., Pisters P.W., et al. Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 2003, 97:2530-2543.
17. Coindre J.M., Terrier P., Bui N.B., et al. Prognostic factors in adult patients with locally controlled soft tissue sarcoma. A study of 546 patients from the French Federation of Cancer Centers Sarcoma Group. J Clin Oncol 1996, 14:869-877.
18. Gerrand C.H., Wunder J.S., Kandel R.A., et al. Classification of positive margins after resection of soft-tissue sarcoma of the limb predicts the risk of local recurrence. J Bone Joint Surg Br 2001, 83:1149-1155.
19. Brennan M.F. Soft tissue sarcoma: advances in understanding and management. Surgeon 2005, 3:216-223.
20. Lewis J.J., Leung D., Espat J., et al. Effect of reresection in extremity soft tissue sarcoma. Ann Surg 2000, 231:655-663.
21. Lin P.P., Guzel V.B., Pisters P.W., et al. Surgical management of soft tissue sarcomas of the hand and foot. Cancer 2002, 95:852-861.
22. Kattan M.W., Leung D.H., Brennan M.F. Postoperative nomogram for 12-year sarcoma-specific death. J Clin Oncol 2002, 20:791-796.
23. Clark M.A., Thomas J.M. Amputation for soft-tissue sarcoma. Lancet Oncol 2003, 4:335-342.
24. Gronchi A.M.R., Shurell E., et al. Predicting survival in primary resected retroperitoneal soft tissue sarcoma: a specific nomogram built on three major sarcoma center data sets. J Clin Oncol 2012, 30:10000.
25. Kattan M.W., Heller G., Brennan M.F. A competing-risks nomogram for sarcoma-specific death following local recurrence. Stat Med 2003, 22:3515-3525.
26. Chibon F., Lagarde P., Salas S., et al. Validated prediction of clinical outcome in sarcomas and multiple types of cancer on the basis of a gene expression signature related to genome complexity. Nat Med 2010, 16:781-787.
27. Italiano A., Largarde P., Brulard C., et al. Genetic profiling identifies two classes of soft-tissue leiomyosarcomas with distinct clinical characteristics. Clin Cancer Res 2013, 19:1190-1196.
28. Lagarde P., Przybyl J., Brulard C., et al. Chromosome instability accounts for reverse metastatic outcomes of pediatric and adult synovial sarcomas. J Clin Oncol 2013, 31:608-615.
29. Sarcoma Meta-analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 1997;350:1647-54.
30. Pervaiz N., Colterjohn N., Farrokhyar F., et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 2008, 113:573-581.
31. Wheatley K., Ives N.J., Eggermont A., et al. Interferon-α as adjuvant therapy for melanoma: an individual patient data meta-analysis of randomised trials. J Clin Oncol 2007, 25:8526.
32. Woll P.J., Reichardt P., Le Cesne A., et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. Lancet Oncol 2012, 13:1045-1054.
33. O'Connor JM, Chacón M, Petracci F.E., Chacón R.D. Adjuvant chemotherapy in soft tissue sarcoma (STS): a meta-analysis of published data. J Clin Oncol 2008, 26:10526.
34. Italiano A., Delva F., Mathoulin-Pelissier S., et al. Effect of adjuvant chemotherapy on survival in FNCLCC grade 3 soft tissue sarcomas: a multivariate analysis of the French Sarcoma Group Database. Ann Oncol 2010, 21:2436-2441.
35. Gronchi A., Frustaci S., Mercuri M., et al. Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group. J Clin Oncol 2012, 30:850-856.
36. Cormier J.N., Huang X., Xing Y., et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J Clin Oncol 2004, 22:4567-4574.
37. Frustaci S., Gherlinzoni F., De Paoli A., et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 2001, 19:1238-1247.
38. Frustaci S., De Paoli A., Bidoli E., et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 2003, 65(suppl 2):80-84.
39. Gortzak E., Azzarelli A., Buesa J., et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 2001, 37:1096-1103.
40. Azzarelli A., Quagliuolo V., Casali P., et al. Preoperative doxorubicin plus ifosfamide in primary soft-tissue sarcomas of the extremities. Cancer Chemother Pharmacol 1993, 31(suppl 2):S210-S212.
41. Meric F., Hess K.R., Varma D.G., et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 2002, 95:1120-1126.
42. Pezzi C.M., Pollock R.E., Evans H.L., et al. Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 1990, 211:476-481.
43. Eilber F.C., Rosen G., Eckardt J., et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 2001, 19:3203-3209.
44. Schuetze S.M., Rubin B.P., Vernon C., et al. Use of positron emission tomography in localized extremity soft tissue sarcoma treated with neoadjuvant chemotherapy. Cancer 2005, 103:339-348.
45. Menendez L.R., Ahlmann E.R., Savage K., et al. Tumor necrosis has no prognostic value in neoadjuvant chemotherapy for soft tissue sarcoma. Clin Orthop Relat Res 2007, 455:219-224.
46. Canter R.J., Qin L.X., Maki R.G., et al. A synovial sarcoma-specific preoperative nomogram supports a survival benefit to ifosfamide-based chemotherapy and improves risk stratification for patients. Clin Cancer Res 2008, 14:8191-8197.
47. Eilber F.C., Brennan M.F., Eilber F.R., et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann Surg 2007, 246:105-113.
48. Italiano A., Penel N., Robin Y.M., et al. Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group. Ann Oncol 2009, 20:425-430.
49. Eilber F.C., Eilber F.R., Eckardt J., et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg 2004, 240:686-695. [discussion 695-687].
50. Donahue T.R., Kattan M.W., Nelson S.D., et al. Evaluation of neoadjuvant therapy and histopathologic response in primary, high-grade retroperitoneal sarcomas using the sarcoma nomogram. Cancer 2010, 116:3883-3891.
51. Hensley M.L., Ishill N., Soslow R., et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol Oncol 2009, 112:563-567.
52. Gronchi A., Bui B.N., Bonvalot S., et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol 2012, 23:771-776.
53. Toma S., Canavese G., Grimaldi A., et al. Concomitant chemo-radiotherapy in the treatment of locally advanced and/or metastatic soft tissue sarcomas: experience of the National Cancer Institute of Genoa. Oncol Rep 2003, 10:641-647.
54. Garcia del Muro X.L.-P.A., Jose Flor M., et al. Phase II study of neoadjuvant high-dose ifosfamide with concurrent radiotherapy followed by surgical resection in high-risk soft tissue sarcoma: a Spanish Group for Research on Sarcomas (GEIS) study. J Clin Oncol 2012, 30:10052.
55. DeLaney T.F., Spiro I.J., Suit H.D., et al. Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 2003, 56:1117-1127.
56. Mullen JT, Kobayashi W, Wang JJ, et al. Long-term follow-up of patients treated with neoadjuvant chemotherapy and radiotherapy for large, extremity soft tissue sarcomas. Cancer 2011;118:3758-65.
57. Kraybill W.G., Harris J., Spiro I.J., et al. Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. J Clin Oncol 2006, 24:619-625.
58. Kraybill WG, Harris J, Spiro IJ, et al. Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation Therapy Oncology Group Trial 9514. Cancer 2010;116:4613-21.
59. American Joint Committee on Cancer Staging Manual 2010, Springer, New York, NY. S.B.B.D. Edge, C.C. Compton, A.G. Fritz, F.L. Green, A. Trotti (Eds.).
60. Omura G.A., Blessing J.A., Major F., et al. A randomized clinical trial of adjuvant adriamycin in uterine sarcomas: a Gynecologic Oncology Group Study. J Clin Oncol 1985, 3:1240-1245.
61. Benjamin R.S., Terjanian T.O., Fenoglio C.J., Barkley H.T., Evans H.L., Murphy W.K., et al. The importance of combination chemotherapy for adjuvant treatment of high-risk patients with soft-tissue sarcomas of the extremities 1987, Grune & Stratton, Orlando.
62. Edmonson J.H., Fleming T.R., Ivins J.C., et al. Randomized Study of systemic chemotherapy following complete excision of nonosseous sarcomas. J Clin Oncol 1984, 2:1390-1396.
63. Chang A.E., Kinsella T., Glatstein E., et al. Adjuvant chemotherapy for patients with high-grade soft-tissue sarcomas of the extremity. J Clin Oncol 1988, 6:1491-1500.
64. Rosenberg S.A., Tepper J., Glatstein E., et al. Prospective randomized evaluation of adjuvant chemotherapy in adults with soft-tissue sarcomas of the extremities. Cancer 1983, 52:424-434.
65. Glenn J., Kinsella T., Glatstein E., et al. A randomized, prospective trial of adjuvant chemotherapy in adults with soft tissue sarcomas of the head and neck, breast, and trunk. Cancer 1985, 55:1206-1214.
66. Glenn J., Sindelar W.F., Kinsella T., et al. Results of multimodality therapy of resectable soft-tissue sarcomas of the retroperitoneum. Surgery 1985, 97:316-325.
67. Bramwell V., Rouesse J., Steward W., et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma-reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1994, 12:1137-1149.
68. Antman K., Suit H., Amato D., et al. Preliminary results of a randomized trial of adjuvant doxorubicin for sarcomas: lack of apparent difference between treatment groups. J Clin Oncol 1984, 2:601-608.
69. Lerner H.J., Amato D.A., Savlov E.D., et al. Eastern Cooperative Oncology Group: a comparison of adjuvant doxorubicin and observation for patients with localized soft tissue sarcoma. J Clin Oncol 1987, 5:613-617.
70. Ravaud A.B.B., Coindre J.-M., Kantor G., et al. Adjuvant chemotherapy with cyvadic in high risk soft tissue sarcoma: a randomised prospective trial 1990, WB Saunders, Philadelphia.
71. Alvegard T.A., Sigurdsson H., Mouridsen H., et al. Adjuvant chemotherapy with doxorubicin in high-grade soft tissue sarcoma: a randomized trial of the Scandinavian Sarcoma Group. J Clin Oncol 1989, 7:1504-1513.
72. Gherlinzoni F., Bacci G., Picci P., et al. A randomized trial for the treatment of high-grade soft-tissue sarcomas of the extremities: preliminary observations. J Clin Oncol 1986, 4:552-558.
73. Antman K.R.L., Borden E., Wood W.C., et al. Pooled results from three randomized adjuvant studies of doxorubicin versus observation in soft tissue sarcoma: 10 year results and review of the literature 1990, WB Saunders, Philadelphia.
74. SAKK. Randomized study of adjuvant chemotherapy with adriamycin and ifosfamide versus observation in patients with soft-tissue srcomas of the extremity and trunk. Unpublished data.
75. Brodowicz T., Schwameis E., Widder J., et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma 2000, 4:151-160.
76. Petrioli R., Coratti A., Correale P., et al. Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 2002, 25:468-473.
77. Issels R.D.A.-R.S., Falk M.H., et al. Initial response to neoadjuvant chemotherapy combined with regional hyperthermia (RHT) In high-risk soft tissue sarcomas (HR-STS) of adults and its correlation to survival parameters. Eur J Cancer 1999, 35:S266.
78. Lucas D.R., Kshirsagar M.P., Biermann J.S., et al. Histologic alterations from neoadjuvant chemotherapy in high-grade extremity soft tissue sarcoma: clinicopathological correlation. Oncologist 2008, 13:451-458.
79. Tateishi U., Kawai A., Chuman H., et al. PET/CT allows stratification of responders to neoadjuvant chemotherapy for high-grade sarcoma: a prospective study. Clin Nucl Med 2011, 36:526-532.
80. Herrmann K., Benz M.R., Czernin J., et al. 18F-FDG-PET/CT imaging as an early survival predictor in patients with primary high-grade soft tissue sarcomas undergoing neoadjuvant therapy. Clin Cancer Res 2012, 18:2024-2031.